Get started
Author

Mónica Cejuela Solís

Observed names: Cejuela M, M. Cejuela, M. Cejuela Solís, Monica Cejuela, Mónica Cejuela, Mónica Cejuela-Solís
Observed institutions: Hospital Universitario Insular de Gran Canaria, Bellvitge University Hospital, Institut Català d'Oncologia, Solti, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla
ORCID: 0000-0002-3894-0765
Observed ORCID: 0000-0002-3894-0765
OpenAlex ID: A5001544018
RETRACTED: Metformin and Breast Cancer: Where Are We Now?
2022 · Mónica Cejuela, Begoña Martin-Castillo, et al. · International Journal of Molecular Sciences · 96
PDF
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
2023 · Mónica Cejuela, Ana Gil-Torralvo, et al. · International Journal of Molecular Sciences · 84
PDF
Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities
2023 · María A. Domínguez-Cejudo, Ana Gil-Torralvo, et al. · International Journal of Molecular Sciences · 43
PDF
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
2022 · Mónica Cejuela, Andrea Vethencourt, et al. · Current Oncology Reports · 40
Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma
2022 · Agostina Stradella, Pablo Gargallo, et al. · Modern Pathology · 13
RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now? Int. J. Mol. Sci. 2022, 23, 2705
2025 · Mónica Cejuela, Begoña Martin-Castillo, et al. · International Journal of Molecular Sciences · 12
PDF
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression
2024 · Isabel Miras, Ana Gil, et al. · Therapeutic Advances in Medical Oncology · 10
Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)
2024 · Manuel Sánchez Cánovas, Javier López Robles, et al. · European Journal of Internal Medicine · 7
PDF
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial
2024 · Bartomeu Fullana, Serafín Morales, et al. · Scientific Reports · 4
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
2023 · Manuel Sánchez-Cánovas, Paula Jimenez-Fonseca, et al. · PLoS ONE · 3
PDF
Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain
2026 · Alejandro Falcón-González, Elisenda Llabrés-Valenti, et al. · Frontiers in Oncology · 2
PDF
Abstract RF5-05: Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations according to their homologous recombination status by the RAD51 test: Primary analysis of the RADIOLA phase II trial
2026 · I. Pimentel, T. Pascual, et al. · Clinical Cancer Research · 2
Clinical features and management for CDK4/6 inhibitor-DILI
2026 · Mar Riveiro-Barciela, Paula Esteban, et al. · JHEP Reports · 1
PDF
Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer.
2024 · Ana Gil, M Ángeles Dominguez-Cejudo, et al. · Journal of Clinical Oncology · 1
HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis.
2023 · Mónica Cejuela Solís, Maria Angeles Castilla, et al. · Journal of Clinical Oncology · 1
Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).
2023 · Isabel Miras, Ana Gil, et al. · Journal of Clinical Oncology · 1
PDF
Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer
2026 · M. Cruellas, A. Rodriguez-Hernandez, et al. · ESMO Open
PDF
Exosomal miRNA balance links estrogen receptor signaling to CDK4/6 inhibitor outcomes
2026 · Maria Angeles Domínguez-Cejudo, Raquel Chapresto-Garzón, et al. · Research Square
PDF
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy
2026 · Sonia Pernas, Xavier Forns, et al. · Clinical & Translational Oncology
PDF
183eTiP SOLTI-2401 HOPE-Focus: A real-world patient-centered study evaluating the feasibility of molecular diagnosis to inform treatment decision-making in patients with metastatic breast cancer in Spain
2026 · T. Pascual, A.M. Casas Fernandez Tejerina, et al. · ESMO Open
520P Eribulin in her-2 negative metastatic breast cancer (mbc): Experience from a multicentric retrospective study across 15 Spanish Hospitals
2026 · J. Torres Sempere, D. Martin Sanchez, et al. · ESMO Open
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer
2026 · Ana Gil-Torralvo, M. Ángeles Domínguez-Cejudo, et al. · Breast Cancer
PDF
Abstract P3-12-01: Eribulin in HER2-negative breast cancer. Results of real world data (RWD) in the era of precision oncology
2025 · Diego Martín Sánchez, Rocío Pérez Velasco, et al. · Clinical Cancer Research
Abstract PO1-27-07: Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative
2024 · Ana Gil-Torralvo, Yeray Rodriguez, et al. · Cancer Research
Abstract P3-01-13: Palbociclib, ribociclib and abemaciclib in real-world data: risk of disease progression on first-line treatment of metastatic breast cancer
2023 · Mónica Cejuela, M. ángeles Castilla, et al. · Cancer Research
Works count: 34
Citation count: 320
H-index: 7
I10-index: 7
Year
Topic
Type